<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="920">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05149170</url>
  </required_header>
  <id_info>
    <org_study_id>CLCG-NKT-2101</org_study_id>
    <nct_id>NCT05149170</nct_id>
  </id_info>
  <brief_title>Radiotherapy and Anti-PD-1 in Low-risk ES-ENKTCL</brief_title>
  <official_title>Radiotherapy With Inductive and Concurrent Anti-PD-1 Antibody in Early-stage Low-risk Extranodal NK/T Cell Lymphoma, Nasal Type: A Multi-center Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Jilin University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Affiliated Cancer Hospital &amp; Institute of Guangzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current study is a phase II multi-center single arm trial to evaluate the efficacy and&#xD;
      safety of adding Anti-PD-1 antibody in an inductive and concurrent way to radiotherapy in&#xD;
      early-stage low-risk extranodal NK/T cell lymphoma, nasal type&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Complete response after inductive therapy</measure>
    <time_frame>2-4 weeks after inductive anti-PD-1 antibody</time_frame>
    <description>complete resolution of disease in imaging and biopsy after inductive therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival rate at year 2 after enrollment, 2y-PFS</measure>
    <time_frame>2-year</time_frame>
    <description>From enrollment to any disease progression or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival rate at year 2/5 after enrollment，2y-/5y-OS</measure>
    <time_frame>2-year, 5-year</time_frame>
    <description>From enrollment to death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of acute toxicity (any and above grade 3)</measure>
    <time_frame>From enrollment to 3 months after treatment</time_frame>
    <description>toxicities according to CTCAE criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life change, QoL</measure>
    <time_frame>baseline, 1/3/6/12/24 months after treatment</time_frame>
    <description>measurement basing on EORTC-QLQ-HN35 tables</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life change, QoL</measure>
    <time_frame>baseline, 1/3/6/12/24 months after treatment</time_frame>
    <description>measurement basing on EORTC-QLQ-C30 tables</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Biomarkers to predict anti-PD-1 antibody efficacy and 2y-PFS</measure>
    <time_frame>baseline</time_frame>
    <description>potential biomarkers in baseline tumor samples and blood samples</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Early-stage</condition>
  <condition>Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type</condition>
  <arm_group>
    <arm_group_label>Inductive and concurrent anti-PD-1 antibody combined with radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All the enrolled patients receive 2 doses of inductive anti-PD-1 antibody (Tislelizumab 200mg) every two weeks, and then Involved-site radiotherapy (50±6-10 Gy) with concurrent anti-PD-1 antibody (Tislelizumab 200mg) every two weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anti-PD-1 monoclonal antibody</intervention_name>
    <description>inductive Anti-PD-1 antibody + concurrent Anti-PD-1 antibody with RT</description>
    <arm_group_label>Inductive and concurrent anti-PD-1 antibody combined with radiotherapy</arm_group_label>
    <other_name>radiotherapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Biopsy proved extranodal NK/T cell lymphoma&#xD;
&#xD;
          -  No previous anti-cancer treatment&#xD;
&#xD;
          -  Measurable lesion on baseline PET/CT and MRI&#xD;
&#xD;
          -  Stage I&#xD;
&#xD;
          -  Normal serum LDH level&#xD;
&#xD;
          -  Primary tumor invasion (PTI) absence&#xD;
&#xD;
          -  ECOG PS 0-1&#xD;
&#xD;
          -  Sufficient organ functions&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other mature T- or NK- lymphoma&#xD;
&#xD;
          -  Hemophagocytic lymphohistiocytosis&#xD;
&#xD;
          -  Primary CNS lymphoma or CNS-involved lymphoma&#xD;
&#xD;
          -  History of malignancy except for cutaneous basal-/squamous- cell carcinoma or cervical&#xD;
             carcinoma in situ 3 years prior to study treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ye-Xiong Li, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CAMS</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shunan Qi, MD</last_name>
    <phone>+8610-87788995</phone>
    <email>medata@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shunan Qi, MD</last_name>
      <phone>+861087788995</phone>
      <email>medata@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>November 6, 2021</study_first_submitted>
  <study_first_submitted_qc>December 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 8, 2021</study_first_posted>
  <last_update_submitted>December 7, 2021</last_update_submitted>
  <last_update_submitted_qc>December 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Shunan Qi</investigator_full_name>
    <investigator_title>Associated Prof. in the radiation oncology department</investigator_title>
  </responsible_party>
  <keyword>NK/T-Cell Lymphoma, Nasal and Nasal-Type</keyword>
  <keyword>radiotherapy</keyword>
  <keyword>Anti-PD-1 Antibody</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, Extranodal NK-T-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All IPD that underlie results in a publication</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>From: 6 months after publication. To: 5 years after publication</ipd_time_frame>
    <ipd_access_criteria>Will share data with the PIs who had specific study plan in immunotherapy area and biomarker area</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

